Walgreens Boots Alliance, Inc.
Case Overview
12 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 11/18/2024 |
Status: | Status: Investigating |
Company Name: | Company Name: Walgreens Boots Alliance, Inc. |
Court: | Court: Northern District of Illinois |
Case Number: | Case Number: 1:24cv08559 |
Class Period: | Class Period: 07/01/2021 - 06/26/2024 |
Ticker: | Ticker: WBA |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of Illinois on behalf of those who acquired Walgreens Boots Alliance, Inc. et al. (“Walgreens” or the “Company”) (NASDAQ: WBA) securities during the period of July 1, 2021 through June 26, 2024, inclusive (“the Class Period”). Investors have until November 18, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On June 27, 2023, Walgreens announced disappointing earnings results for the fiscal third quarter of 2023, slashed its fiscal year 2023 guidance, and revealed that it was "experiencing a slower profit ramp for U.S. Health Care" due to "VillageMD [] underperformance." On this news, the price of Walgreens shares declined from a price of $31.59 per share on June 26, 2023, to a closing price of $28.64 per share on June 27, 2023.
On July 27, 2023, Walgreens announced the departure of its Chief Financial Officer. On this news, the price of Walgreens shares declined from a closing price of $30.63 per share on July 27, 2023, to a closing of $29.80 per share on July 28, 2023. On September 1, 2023, Walgreens announced the departure of its Chief Executive Officer. On this news, the price of Walgreens shares declined from a closing price of $25.31 per share on August 31, 2023, to a closing price of $23.43 per share on September 1, 2023.
On January 4, 2024, Walgreens announced disappointing financial results for the fiscal first quarter of 2024, which analysts attributed to operations in the VillageMD clinics. On this news, the price of Walgreens shares declined from a closing price of $25.57 per share on January 3, 2024, to a closing price of $24.26 per share on January 4, 2024.
Finally, on June 27, 2024, Walgreens announced that its financial results for the fiscal third quarter of 2024 were well below expectations. On that same day, in an interview with The Wall Street Journal, Walgreens' new Chief Executive Officer said that the Company would reduce its stake in VillageMD, and would no longer be its majority owner. On this news, the price of Walgreens shares declined by $3.47 per share, or over 22%, from a closing price of $15.66 per share on June 26, 2024, to a closing price of $12.19 per share on June 27, 2024.
The lawsuit alleges that Walgreens made materially false and/or misleading statements and failed to disclose material adverse facts about the Company's business, operations, and prospects, including that: (1) despite repeated assurances, Walgreens was not disciplined about deploying capital to grow the U.S. Healthcare segment and did not know how to work with and scale its VillageMD model; (2) Walgreens was not able to profitably scale VillageMD to support the Company's long-term growth initiatives; (3) Walgreens' rollout of VillageMD clinics was not going according to plan; (4) Walgreens' U.S. Healthcare segment was experiencing slower growth than expected because Walgreens had oversaturated markets with VillageMD clinics, leading these newly created medical clinics to be understaffed and see fewer patients; and (5) Walgreens executives had failed to manage investor expectations regarding the negative impact that the VillageMD expansion would have on Walgreens' short-term profits, overstatement of the value of VillageMD, and the risk that the Company would be forced to divest part or all of its stake in VillageMD.
On June 27, 2023, Walgreens announced disappointing earnings results for the fiscal third quarter of 2023, slashed its fiscal year 2023 guidance, and revealed that it was "experiencing a slower profit ramp for U.S. Health Care" due to "VillageMD [] underperformance." On this news, the price of Walgreens shares declined from a price of $31.59 per share on June 26, 2023, to a closing price of $28.64 per share on June 27, 2023.
On July 27, 2023, Walgreens announced the departure of its Chief Financial Officer. On this news, the price of Walgreens shares declined from a closing price of $30.63 per share on July 27, 2023, to a closing of $29.80 per share on July 28, 2023. On September 1, 2023, Walgreens announced the departure of its Chief Executive Officer. On this news, the price of Walgreens shares declined from a closing price of $25.31 per share on August 31, 2023, to a closing price of $23.43 per share on September 1, 2023.
On January 4, 2024, Walgreens announced disappointing financial results for the fiscal first quarter of 2024, which analysts attributed to operations in the VillageMD clinics. On this news, the price of Walgreens shares declined from a closing price of $25.57 per share on January 3, 2024, to a closing price of $24.26 per share on January 4, 2024.
Finally, on June 27, 2024, Walgreens announced that its financial results for the fiscal third quarter of 2024 were well below expectations. On that same day, in an interview with The Wall Street Journal, Walgreens' new Chief Executive Officer said that the Company would reduce its stake in VillageMD, and would no longer be its majority owner. On this news, the price of Walgreens shares declined by $3.47 per share, or over 22%, from a closing price of $15.66 per share on June 26, 2024, to a closing price of $12.19 per share on June 27, 2024.
The lawsuit alleges that Walgreens made materially false and/or misleading statements and failed to disclose material adverse facts about the Company's business, operations, and prospects, including that: (1) despite repeated assurances, Walgreens was not disciplined about deploying capital to grow the U.S. Healthcare segment and did not know how to work with and scale its VillageMD model; (2) Walgreens was not able to profitably scale VillageMD to support the Company's long-term growth initiatives; (3) Walgreens' rollout of VillageMD clinics was not going according to plan; (4) Walgreens' U.S. Healthcare segment was experiencing slower growth than expected because Walgreens had oversaturated markets with VillageMD clinics, leading these newly created medical clinics to be understaffed and see fewer patients; and (5) Walgreens executives had failed to manage investor expectations regarding the negative impact that the VillageMD expansion would have on Walgreens' short-term profits, overstatement of the value of VillageMD, and the risk that the Company would be forced to divest part or all of its stake in VillageMD.